Gastrointestinal stromal tumors, or GISTs, most commonly occur in the stomach or small intestine. GISTs with a certain type of mutation don’t respond to typical GIST therapies, and Ayvakit is the first drug approved to target the specific mutation, which occurs in about 10 percent of GISTs.
Ayvakit is a kinase inhibitor, meaning it blocks a type of enzyme called a kinase that helps keep cancer cells from growing.
In clinical trials, almost 85 percent of patients saw tumor shrinkage with Ayvakit.
The drug was granted breakthrough therapy designation, fast track designation and orphan drug designation.
Read the full news release here.
More articles on pharmacy:
GAO report hits lax oversight of 340B drug program
Venture capitalist launches company to bring drug prices down
AMAG Pharmaceuticals replacing CEO, cutting 2 drugs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.